Combination of ruthenium (II) polypyridyl complex Δ-Ru1 and Taxol enhances the anti-cancer effect on Taxol-resistant cancer cells through Caspase-1/GSDMD …
D Chen, S Guo, X Tang, Y Rong, H Bo, H Shen… - Journal of Inorganic …, 2022 - Elsevier
Taxol is the first-line drug for cancer treatment. However, tumor resistance to Taxol is still a
significant challenge in clinical practice. Here, we studied the synergistic effect of a …
significant challenge in clinical practice. Here, we studied the synergistic effect of a …
Combination of ruthenium (II) polypyridyl complex Δ-Ru1 and Taxol enhances the anti-cancer effect on Taxol-resistant cancer cells through Caspase-1/GSDMD …
D Chen, S Guo, X Tang, Y Rong, H Bo… - Journal of Inorganic …, 2022 - europepmc.org
Taxol is the first-line drug for cancer treatment. However, tumor resistance to Taxol is still a
significant challenge in clinical practice. Here, we studied the synergistic effect of a …
significant challenge in clinical practice. Here, we studied the synergistic effect of a …
Combination of ruthenium (II) polypyridyl complex Δ-Ru1 and Taxol enhances the anti-cancer effect on Taxol-resistant cancer cells through Caspase-1/GSDMD …
D Chen, S Guo, X Tang, Y Rong… - Journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
Taxol is the first-line drug for cancer treatment. However, tumor resistance to Taxol is still a
significant challenge in clinical practice. Here, we studied the synergistic effect of a …
significant challenge in clinical practice. Here, we studied the synergistic effect of a …